Form 4 Filing for 4D Molecular Therapeutics, Inc.

David Kirn, President and Chief Executive Officer of 4D Molecular Therapeutics, Inc., reported a sale of 114,746 shares of common stock on June 22, 2026. The transaction was executed under a 10b5-1 trading plan at a weighted average price of $10.4653 per share, with individual trades ranging from $10.00 to $10.87. Following this transaction, Mr. Kirn directly owns 942,485 shares of common stock. The filing details the sale of shares at a weighted average price and provides an undertaking to furnish further information regarding specific prices upon request.